Meet the Press

Thursday, August 14 2014
8:00 am – 10:00 am

Location: MassBio, 300 Technology Square, 8th Floor, Cambridge, MA

Massachusetts is home to medical innovation and biotechnology breakthroughs. Breaking news happens daily here.  This session will provide you will the rare opportunity to meet some of the beat and feature reporters covering the healthcare and life sciences industries in Massachusetts. The panel discussion will provide insight into how journalists choose stories and how you can make your best pitch to get your latest invention, breakthrough or deal covered.

Speakers:

  • Priyanka Dayal McCluskey, Business Reporter, Boston Globe
  • Heidi Ledford, Ph.D., Reporter, Nature Magazine
  • Don Seiffert, BioFlash Editor, Boston Business Journal, Associate Editor, Mass High Tech

Moderator:

  • Daniel J. McIntyre, SVP, Public Affairs, Biogen Idec

 

This Forum is presented by the Marketing/Communications Forum Working Group.

Bios:


Priyanka Dayal McCluskey, Business Reporter, Boston Globe

Priyanka writes about health care and biotechnology for the Boston Globe. She came to the Globe from the Boston Herald, where she covered health care. Previously, she was a business reporter and local news reporter at the Worcester Telegram & Gazette. Priyanka grew up in Central Massachusetts and graduated from Boston University. In 2012, the New England Society of Newspaper Editors named her New England journalism’s “Rising Star," and in 2014, the New England chapter of the American Medical Writers Association gave her the Will Solemine Award for Excellence in Medical Writing for a series on hospital-acquired infections.

Heidi Ledford, Ph.D., Reporter, Nature Magazine

Heidi Ledford is a senior reporter at Nature, where she covers biomedicine (particularly cancer), biotech, pharma, patents and a handful of other topics (including agricultural biotechnology). Heidi has written for The Oregonian, edited for the Berkeley Science Review, and freelances a bit here and there when she can find the time. She has a PhD (in plant biology) from the University of California at Berkeley, and is now based in Cambridge, Mass

Daniel J. McIntyre, SVP, Public Affairs, Biogen Idec

Daniel McIntyre is senior vice president of Corporate Affairs for Biogen Idec, where he is responsible for global communication, government affairs, employee communication and community relations. He also serves on the board of directors of the Biogen Idec Foundation and the California Healthcare Institute, and is treasurer of the company’s political action committee. Dan has more than 30 years of experience in public affairs, at the point where communications, public policy and issues management intersect. His expertise includes pharmaceuticals, biologicals and biotechnology, diagnostics and providers. Dan has held the top global position in communications and/or public policy at Wyeth, Pharmacia, and Bayer Pharmaceutical Division. He has counseled two CEOs during their chairmanships of the pharmaceutical trade association, PhRMA, the Healthcare Institute of New Jersey and the New England Healthcare Institute.

Dan has led patient advocacy programs including “Take It To Heart,” with the National Medical Association and National Black Nurses Association, which screened for health conditions in minority communities; “Operation Clean Hands,” a hygiene education program conducted in partnership with the International Society of Microbiology; and “Parents Empowering Parents” with the National Hemophilia Foundation. He also led the communication team supporting PhRMA in RxResponse, a coalition to ensure pharmaceutical supplies in the event of a natural disaster, pandemic or act of bioterrorism.

Dan’s experience in public and government affairs on high-profile issues covers medical product safety and supply; screening and access to therapies in at-risk communities; conduct and reimbursement of clinical trials in the U.S. and developing countries; and pricing of pharmaceutical and biotechnology therapies. He directed Bayer’s public affairs efforts concerning the contamination of anti-hemophilic factor with HIV/AIDS and a worldwide shortage of immune globulins, which included hearings of U.S. congressional oversight subcommittees and the U.S. Department of Health and Human Services, as well as national media coverage that included 60 Minutes.

Dan also has led public affairs efforts for the first ever worldwide product withdrawal linked to Creutzfeldt-Jakob disease; use of antibiotics in food animals; patent extensions under the FDA Modernization Act of 1997; and anthrax labeling for the antibiotic CIPRO. He was a member of Roche’s first national accounts organization, specializing in health economics and third-party coverage for antibiotics, oncology therapies and patient care under clinical trials.

Dan serves on the executive committee of the Rutgers University Foundation, and is a past member of the boards of Caldwell College, the American Association for World Health, the New England Healthcare Institute (NEHI), and Connecticut United for Research Excellence (CURE). He is an honors graduate of Seton Hall University and holds a master’s in public administration from Rutgers University, where he received the E. Drexel Godfrey Award for Academic Excellence.

Don Seiffert, BioFlash Editor, Boston Business Journal, Associate Editor, Mass High Tech

Don Seiffert covers biotechnology, pharmaceutical, diagnostic and medical device companies for the Boston Business Journal. He has been a journalist in the Boston area since 1996, previously covering community news as editor of the Newton TAB from 2000-2006, where the paper won Newspaper of the Year by the national Suburban Newspaper Association in 2001, 2002 and 2006, and by the New England Newspaper Association in 2004. Seiffert has also won awards for reporting on health, business and human interest topics by the New England Press Association. Seiffert was an editor at the Brockton Enterprise from 2006-2010. He now lives in Salem and has two children. He used to write a blog about tea but then got too busy.

 

Share MassBio

 

Janitronics

EvaluatePharma


 

MassBio